Further Delineation of Pyridoxine-Responsive Pyridoxine Phosphate Oxidase Deficiency Epilepsy: Report of a New Case and Review of the Literature With Genotype-Phenotype Correlation.
Licia LugliMaria Carolina BariolaLuca OriLaura LucaccioniAlberto BerardiFabrizio FerrariPublished in: Journal of child neurology (2019)
In recent years, the clinical spectrum of pyridoxine phosphate oxidase (PNPO) deficiency has broadened. There are a growing number of patients with a transient or lasting response to pyridoxine in addition to cases that respond more traditionally to pyridoxal-phosphate. However, among pyridoxine-responsive patients with PNPO gene mutation, there are only a few reports on electroencephalogram (EEG) ictal/interictal patterns, and data regarding the outcomes are inconsistent. We describe a case of neonatal onset epilepsy with missense mutation c(674G>A) p(R225 H) in PNPO gene and pyridoxine responsiveness. Comparing this patient with 24 cases of previously described pyridoxine-responsive pyridoxine phosphate oxidase deficiency epilepsy, we found that patients carrying the missense mutation c(674G>A) p(R225 H) of the PNPO gene might have a more severe epileptic phenotype, possibly because of their lower residual PNPO activity. Indeed, pyridoxine-responsive pyridoxine phosphate oxidase deficiency epilepsy remains a challenge, with neurodevelopmental disabilities occurring in about half of the cases.
Keyphrases
- genome wide
- cancer therapy
- type diabetes
- emergency department
- ejection fraction
- end stage renal disease
- working memory
- intellectual disability
- newly diagnosed
- drug delivery
- autism spectrum disorder
- artificial intelligence
- electronic health record
- blood brain barrier
- skeletal muscle
- transcription factor
- smoking cessation
- replacement therapy
- subarachnoid hemorrhage
- drug induced
- glycemic control